Insight Molecular Diagnostics (IMDX) Invested Capital (2015 - 2026)

Insight Molecular Diagnostics has disclosed Invested Capital across 12 years of filings, most recently posting -$10.5 million for Q1 2026.

• Invested Capital for Q1 2026 came in at -$10.5 million, down 196.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.5 million (down 196.32% YoY), and the FY2025 annual result was -$31.0 million, down 157.65% from the prior year.
• Invested Capital came in at -$10.5 million for Q1 2026 at Insight Molecular Diagnostics, up from -$31.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $83.9 million in Q2 2022 to a low of -$31.0 million in Q4 2025.
• The 5-year median for Invested Capital is $22.8 million (2023), against an average of $22.9 million.
• Across the five-year window, Invested Capital slipped 5.64% in 2025 and slumped 196.32% in 2026, its largest moves.
• Insight Molecular Diagnostics' Invested Capital stood at $34.4 million in 2022, then tumbled by 33.78% to $22.8 million in 2023, then plunged by 152.88% to -$12.0 million in 2024, then tumbled by 157.65% to -$31.0 million in 2025, then surged by 66.07% to -$10.5 million in 2026.
• The last three Invested Capital figures came in at -$10.5 million (Q1 2026), -$31.0 million (Q4 2025), and -$8.1 million (Q3 2025), per Business Quant data.